In this study, we found the levels of aCL and ESR decreased significantly after RTX treatment, and there were no significant differences in CR rate, aβ2GPI titers, LAC or adverse events for 6 months between patients taking low and standard doses of RTX for APS. Here, ESR1 is linked to autoimmune polyendocrinopathy.